Clinical Trial Update: A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL [Phase 1]

View source ↗

Summary

This report summarizes the completion of a Phase 1 study of WU-CART-007, an allogeneic anti-CD7 CAR-T cell therapy, in patients with relapsed or refractory T-ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Lymphoma
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• WU-CART-007

Snippet

Sponsor: Wugen, Inc. | Conditions: T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | Status: COMPLETED